Study Title
PNOC022: A combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGS) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression
Protocol ID
PNOC022
Condition/s
Diffuse Intrinsic Pontine Glioma
Diffuse Midline Glioma, H3 K27M-Mutant
Recurrent Diffuse Intrinsic Pontine Glioma
Recurrent Diffuse Midline Glioma, H3 K27M-Mutant
Recurrent WHO Grade III Glioma
WHO Grade III Glioma
Diffuse Midline Glioma, H3 K27M-Mutant
Recurrent Diffuse Intrinsic Pontine Glioma
Recurrent Diffuse Midline Glioma, H3 K27M-Mutant
Recurrent WHO Grade III Glioma
WHO Grade III Glioma
Diagnosis Stage
Newly diagnosed
Relapsed/Refractory
Relapsed/Refractory
Location
NSW, QLD, VIC, WA, SA, NZ
Sponsor
Australian and New Zealand Children's Haematology Oncology Group
Collaborators
Pacific Pediatric Neuro-Oncology Consortium
Links
Trial Status
Temporarily Closed
Sites
The Children's Hospital at Westmead
Royal Children's Hospital
Queensland Children's Hospital
Perth Children's Hospital
Women's and Children's Hospital
Monash Children's Hospital
Sydney Children's Hospital
John Hunter Children's Hospital
Starship Hospital
Royal Children's Hospital
Queensland Children's Hospital
Perth Children's Hospital
Women's and Children's Hospital
Monash Children's Hospital
Sydney Children's Hospital
John Hunter Children's Hospital
Starship Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
2 Years to 39 Years
International registry ID's
NCT05009992
| Study Title | PNOC022: A combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGS) at Initial Diagnosis Post-Radiation Therapy and at Time of Progression |
|---|---|
| Protocol ID | PNOC022 |
| Disease (Sub Disease) | Diffuse Intrinsic Pontine Glioma Diffuse Midline Glioma, H3 K27M-Mutant Recurrent Diffuse Intrinsic Pontine Glioma Recurrent Diffuse Midline Glioma, H3 K27M-Mutant Recurrent WHO Grade III Glioma WHO Grade III Glioma |
| Diagnosis Stage | Newly diagnosed Relapsed/Refractory |
| Location | NSW / QLD / VIC / WA / SA / NZ |
| Sponsor | Australian and New Zealand Children's Haematology Oncology Group |
| Collaborators | Pacific Pediatric Neuro-Oncology Consortium |
| Links | https://clinicaltrials.gov/ct2/show/NCT05009992 |
| Trial Status | Temporarily Closed |
| Trial Open Date | 18/08/2022 |
| Sites | The Children's Hospital at Westmead/ Royal Children's Hospital / Queensland Children's Hospital/ Perth Children's Hospital/ Women's and Children's Hospital/ Monash Children's Hospital/ Sydney Children's Hospital/ John Hunter Children's Hospital/ Starship Hospital |
| Study Type | Treatment |
| Phase | Phase 1/2 |
| Age Eligibility | 2 Years to 39 Years |
| International registry ID's | NCT05009992 |